Science | Nature | Cell | View More
Screening Libraries
Chemosensitizers Compound Library
A unique collection of 11 Chemosensitizers Compound Library for high throughput screening (HTS), high content screening (HCS) and New drug research
Cat. Size Price Stock
L202131mg/well * 11 CompoundsInquiry In stock
Contact Us
L20213100uL/well (10mM solution) * 11 CompoundsInquiry In stock
*You can select compounds, quantities, format (dry/solid or DMSO) and plate map to meet your specific requirement.
Contact Us
E-mail manager@chemfaces.com
Tel (0086)-27-8423-7683
Shelf Life (0086)-27-84254680
ManufacturerWuhan ChemFaces Biochemical Co., Ltd.
Package & Storage
Container 96 Well Format Sample
Storage Protected from air and light, refrigerate or freeze(2-8 °)
Shelf Life 24 months (2-8 °)
Intended UseFor research use only. Not for human use. Not sell to patients
Description & Advantages
1. The products in the ChemFaces screening libraries are all from plants.
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research.
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools.
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity.
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution).
Natural Products
Catalog No. Information
CFN99647 5,5'-Dimethoxylariciresinol 4-O-glucoside

5,5'-Dimethoxylariciresinol-4'-O-beta-D-glucoside is shown to effectively enhance chemosensitivity of resistant cells, which makes it may be a suitable candidate for potential multidrug resistance (MDR)-reversing agents.
CFN98737 Orobol

Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover, it has sensitization effect, it can produce produced cisplatin (DDP) sensitivity in human ovarian carcinoma cells by inducing apoptosis through the MT-dependent signaling pathway. Orobol and platelet derived growth factor (PDGF) regulate paclitaxel (PX) sensitivity by reciprocally altering the proportion of tubulin isotype expression and PX-induced apoptotic signaling. Orobol exhibits antiviral effects against some animal viruses, addition of the compound after virus entry inhibits the appearance of late viral protein synthesis in Vesicular Stomatitis Virus, influenza, or vaccinia virus-infected cells, but has no effect on poliovirus protein synthesis.
CFN97245 Lupalbigenin

Lupalbigenin sensitizes detachment-induced cell death in human lung cancer cell through down-regulation of pro-survival proteins.Lupalbigenin, laburnetin , and isolupalbigenin show promising cytotoxic effects toward HL-60 cells (IC50 4.3 ± 0.7 to 18.0 ± 1.7 uM).
CFN97283 Schinifoline

Schinifoline has cytotoxic activity, it also shows in vitro radiosensitising, cell cycle and apoptotic-inducing effects.
CFN90421 4-Methylumbelliferone

4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM, which has antitumoral and antimetastatic effects. 4-Methylumbelliferone may inhibit the phosphorylation of HAS2 by PKC through the stimulation of O-GlcNAcylation; it also similarly ameliorates hypertriglyceridemia and hyperglycemia partly by modulating hepatic lipid metabolism and the antioxidant defense system along with increasing adiponectin levels.
CFN90481 Cimicifugoside

Cimicifugoside is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function. Cimicifugoside is also a phytoestrogen, it can selectively inhibit nicotinic acetylcholine receptor (nAChR) -mediated response in bovine chromaffin cells.
CFN92073 Kuguacin J

Kuguacin J is a promising candidate new antineoplastic and chemopreventive agent for androgen-dependent prostate cancer and carcinogenesis, it exerts growth inhibition through G1 arrest and induction of apoptosis in androgen-dependent human prostate cancer. Kuguacin J modulates the function of P-glycoprotein (P-gp) by directly interacting at the drug-substrate-binding site, and it appears to be an effective inhibitor of P-gp activity in vitro and thus could be developed as an effective chemosensitizer to treat multidrug-resistant cancers.
CFN92658 Yangonin

Yangonin is a novel CB₁ receptor ligand, it exhibits affinity for the human recombinant CB₁ receptor, it is also an effective inhibitor of EV-A71 infection in the low-micromolar. Yangonin could be a valuable candidate for the intervention of NF-κB-dependent pathological conditions such as inflammation.Yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway.
CFN90928 Cyclopamine

Cyclopamine is a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay, it can increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cyclopamine as a novel, potent inhibitor of human breast cancer proliferation and estrogen responsiveness that could potentially be developed into a promising therapeutic agent for the treatment of breast cancer. Cyclopamine also can suppress the growth of leukemia and lymphoma cells.
CFN93261 Cisplatin

Cisplatin is a antineoplastic chemotherapy drug which works by cross-linking with DNA and causing DNA damage in cancer cells, it can enhance the cell-killing effect of radiation, an effect whose intensity varies with the schedule of administration.